For research use only. Not for therapeutic Use.
AZD5582 dihydrochloride (CAT: I015386) is a potent antagonist of inhibitor of apoptosis proteins (IAPs), specifically binding to the BIR3 domains of cIAP1, cIAP2, and XIAP with IC50 values of 15, 21, and 15 nM, respectively. This compound induces apoptosis by downregulating cIAP-1, activating RIPK1, and triggering both extrinsic (caspase-8) and intrinsic (caspase-9) apoptosis pathways, resulting in the cleavage of caspase-3 and caspase-7. AZD5582 demonstrates synergistic effects with IFNγ or viral double-stranded RNA (dsRNA) to inhibit cell viability in NSCLC cells. In preclinical studies, AZD5582 administration leads to the degradation of cIAP1, caspase 3 cleavage, and tumor regression.
| Catalog Number | I015386 |
| CAS Number | 1883545-51-4 |
| Molecular Formula | C₅₈H₈₀Cl₂N₈O₈ |
| Purity | ≥95% |
| Target | IAP |
| Reference | [1]. Hennessy EJ, et al. Discovery of a novel class of dimeric Smac mimetics as potent IAP antagonists resulting in a clinical candidate for the treatment of cancer (AZD5582). J Med Chem. 2013 Dec 27;56(24):9897-919.<br>[2]. Qin Hao, et al. IF-γ and Smac mimetics synergize to induce apoptosis of lung cancer cells in a TNFα-independent manner,Cancer Cell Int. 2018; 18: 84. |
